German COVID-19 Vaccine Producer Strategically Expands Production Capacity

Germany based BioNTech SE announced on September 17, 2020, the signing of a share purchase agreement with Novartis AG to acquire its certified manufacturing facility in Marburg, Germany. The transaction is expected to close in the fourth quarter of 2020.

This manufacturing site will expand BioNTech’s COVID-19 vaccine production capacity by up to 750 million of the BNT162b2 vaccine candidate doses per year, or over 60 million doses per month, once fully operational.